doi: 10.1007/s00520-022-07312-y.
- PMID: 35933415
- DOI: 10.1007/s00520-022-07312-y
Abstract
Purpose: To assess the safety, dosing, and preventive effects of cannabidiol (CBD) on chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving oxaliplatin- or paclitaxel-based chemotherapy.
Methods: Patients with cancer scheduled to undergo treatment with carboplatin and paclitaxel (Carbo-Tax) or capecitabine and oxaliplatin (CAPOX) received 150 mg CBD oil twice daily (300 mg/daily) for 8 days beginning 1 day before initiation of chemotherapy. Ten CIPN-specific patient-reported outcome (PRO) measures were captured at baseline and each day after the first cycle of chemotherapy for 8 days. Multi-frequency vibrometry (MF-V) was captured at baseline and day 4 ± 1 after initiation of chemotherapy. Controls were obtained from a similar patient cohort that did not receive CBD. Adverse events were captured using the CTCAE ver. 4.03.
Results: From March to December 2021, 54 patients were recruited. CBD-treated patients were significantly older (p = 0.013/0.037, CAPOX/Carbo-Tax) compared to controls. Patients receiving CBD and CAPOX or Carbo-Tax showed significantly lower (better) change in Z-scores in high-frequency MF-V (125 and 250 Hz) compared to controls. This difference was most pronounced for patients receiving Carbo-Tax (- 1.76, CI-95 = [- 2.52; – 1.02] at 250 Hz). CAPOX patients treated with CBD had significantly lower peak baseline-adjusted difference in three PRO items on cold sensitivity to touch, discomfort swallowing cold liquids, and throat discomfort (- 2.08, – 2.06, and – 1.81, CI-95 = [- 3.89; – 0.12], NRS 0-10). No significant differences in PRO items were found for patients receiving Carbo-Tax. Possible side effects included stomach pain (grades 1-2) for patients receiving CAPOX.
Conclusion: CBD attenuated early symptoms of CIPN with no major safety concerns. Long-term follow-up is ongoing. Results should be confirmed in a larger, randomized study.
Trial registration number: NCT 04,167,319 (U.S National Library of Medicine; ClinicalTrials.gov). Date of registration: November 18, 2019.
Keywords: Cannabinoid, Chemotherapy-induced peripheral neuropathy, Oxaliplatin-induced peripheral neuropathy, Paclitaxel-induced peripheral neuropathy, Peripheral neuropathy
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes.J Clin Med. 2022 Mar 27;11(7):1862. doi: 10.3390/jcm11071862.PMID: 35407470 Free PMC article.
-
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).Support Care Cancer. 2021 Feb;29(2):833-840. doi: 10.1007/s00520-020-05543-5. Epub 2020 Jun 4.PMID: 32500206 Free PMC article.
-
Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.Support Care Cancer. 2019 Dec;27(12):4771-4777. doi: 10.1007/s00520-019-04781-6. Epub 2019 Apr 10.PMID: 30972648
-
Prevention and treatment of chemotherapy-induced peripheral neuropathy.Am J Health Syst Pharm. 2014 Jan 1;71(1):19-25. doi: 10.2146/ajhp130126.PMID: 24352178 Review.
-
Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.Support Care Cancer. 2022 Jan;30(1):33-47. doi: 10.1007/s00520-021-06502-4. Epub 2021 Aug 19.PMID: 34410459 Review.
References
-
- Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470. https://doi.org/10.1016/j.pain.2014.09.020 – DOI – PubMed
-
- Miura Y, Ando M, Yamazaki K et al (2021) Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). Support Care Cancer 29:3715–3723. https://doi.org/10.1007/s00520-020-05891-2 – DOI – PubMed
-
- Pellacani C, Eleftheriou G (2020) Neurotoxicity of antineoplastic drugs: mechanisms, susceptibility, and neuroprotective strategies. Adv Med Sci 65:265–285. https://doi.org/10.1016/j.advms.2020.04.001 – DOI – PubMed
-
- Si Z, Zhang S, Yang X et al (2019) The association between the incidence risk of peripheral neuropathy and PD-1/PD-L1 inhibitors in the treatment for solid tumor patients: a systematic review and meta-analysis. Front Oncol 9:1–10. https://doi.org/10.3389/fonc.2019.00866 – DOI
-
- Laforgia M, Laface C, Calabrò C et al (2021) Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. Int J Mol Sci 22:1980. https://doi.org/10.3390/ijms22041980 – DOI – PubMed – PMC
